Latest Headlines

Latest Headlines

Soligenix nabs up to $24.7M NIH contract for bioterror vaccine

Soligenix won a grant for up to $24.7 million from the U.S. National Institutes of Health to advance its thermostabilization technology, ThermoVax, in combination with the company's ricin toxin vaccine, RiVax, as a medical countermeasure to prevent the effects of ricin exposure.

Billionaire Kirk grabs $150M round for synthetic biology deals at Intrexon

A day after striking the latest in a series of its special "channel" collaborations, Intrexon has reloaded its bank account with a fresh $150 million infusion of cash, with significant added contributions from billionaire founder R.J. Kirk and his venture fund, Third Security.

Soligenix, Infectious Disease Research Institute partner to combat anthrax

Soligenix, a Princeton, NJ-based biopharmaceutical company, will partner with the Infectious Disease Research Institute of Seattle, to develop biodefense vaccines.

Army researcher develops microemulsion vaccine carrier

A microemulsion vaccine carrier, developed by U.S. Army Maj. Jean M. Muderhwa and presented at Experimental Biology 2012, has the potential to improve the stability of vaccines.

UPDATED: Soligenix shares decimated on repeat failure for orBec Ph3

Princeton, NJ-based Soligenix ($SGNX) called a sudden halt to its late-stage study of orBec--an oral formulation of beclomethasone dipropionate for acute gastrointestinal Graft-versus-Host

Soligenix gets oral, topical GI steroids patent

Soligenix has been granted European Patent 1392321, "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The patent covers the use of